muscular dystrophy

PepGen Inc’s (NASDAQ: PEPG) lead asset, PGN-EDO51 for Duchenne muscular dystrophy (DMD), is in phase 1 clinical trials in healthy volunteers with data expected by the end of the year, according to BofA Securities. The PepGen Analyst: Tazeen Ahmad initiated coverage of PepGen with a Buy rating...

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear DMPK RNA, the genetic basis of the disease. Data were presented at the American...

The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on track to report full data from the ReDUX4 Phase 2b trial at the virtual FSHD...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) saw a marked decline this week after Food and Drug Administration scientists said studies examining the effects of the firm's latest muscular dystrophy drug were inconsistent. The FDA's review of Sarepta's drug followed a similar dismissal of...